Formation Bio Launches $600M Fund to Acquire 10-15 Drug Programs
New York – October 29, 2026 -- Formation Bio, an AI-native pharmaceutical company, has launched the Formation Bio Drug Development Accelerator Fund with $600 million in capital commitments to expand its portfolio of clinical-stage medicines. The company aims to acquire 10-15 drug programs over the next 3-5 years and advance them through key clinical milestones.
Fund draws research foundations, endowments and hospitals as limited partners
The Fund's limited partners include research foundations, institutional endowments, hospitals and philanthropic organizations. Formation Bio acts as general partner through a wholly owned subsidiary and has committed its own capital alongside them. The amount of that commitment was not disclosed.
The Fund exclusively finances the acquisition and development of programs within Formation Bio's portfolio, scaling the company's hub-and-spoke model.